EMERYVILLE, Calif.–(BUSINESS WIRE)–Mar 23, 2020–
. (NYSE American: NBY) today unveils a rebrand for non-prescription Avenova, its antimicrobial lid and lash solution. The comprehensive refresh reinforces the Company’s strategy of reaching a broader audience through and .
This press release features multimedia. View the full release here:
Avenova Lid & Lash Solution’s new consumer branding (Photo: Business Wire)
Avenova is the only patented, FDA-cleared formula that uses pure hypochlorous acid to treat issues like bacterial dry eye, blepharitis and contact lens intolerance.
“The goal of the rebrand is to make the sophisticated science behind our product accessible and appealing to the end consumer. It also reflects influence from the beauty industry as Avenova is not only about taking care of you see but also ,” said Justin Hall, NovaBay CEO. “We firmly believe that Avenova is the safest and most effective product available for the topical treatment of bacterial infections that affect the majority of patients with chronic dry eye disease. To build on the momentum we have experienced with Avenova online sales, we are refreshing our consumer product messaging and packaging. Our reinvigorated branding is being combined with cost-efficient social media to entice new customers to try Avenova. Once people try our product, we are confident that many will become repeat customers.
“Now that prescription-strength Avenova is available directly to the end consumer without a prescription, we thought it was important to have the brand clearly convey our core values. A scientific approach to personal care is reflected in the ” ” and ” ” themes represented in our new communications. We expect our refreshed branding to be more attractive to a broader base of consumers who shop online seeking a gentle yet powerful antimicrobial solution. Our plan is to have the new packaging available to consumers for online sales within the next few months, while prescription Avenova sold through pharmacies will continue to retain the current packaging.”
Please visit to explore the new website and learn more about Avenova.
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX ® family of products and the AGANOCIDE ® compounds. The Neutrox family of products includes AVENOVA ® for the eye care market, CELLERX ® for the aesthetic dermatology market NEUTROPHASE ® for wound care market.
View source version on businesswire.com:
CONTACT: NovaBay Contact
Justin Hall
CEO and General Counsel
510-899-8800
Investor Contact
LHA Investor Relations
Jody Cain
310-691-7100
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: OTHER CONSUMER MARKETING COMMUNICATIONS BIOTECHNOLOGY PHARMACEUTICAL CONSUMER HEALTH OPTICAL RETAIL ONLINE RETAIL
SOURCE: NovaBay Pharmaceuticals, Inc.
Copyright Business Wire 2020.
PUB: 03/23/2020 06:50 AM/DISC: 03/23/2020 06:50 AM
COMMENTS
Please let us know if you're having issues with commenting.